Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 59

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 59
---
Accumulated deficit

			(61,858,769
			)

			(58,589,013
			)

			Total shareholders' equity

			15,539,598

			1,981,155

			Total liabilities and shareholders' equity

			$
			16,454,299

			$
			3,813,982

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

3

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Operations

			Three Months Ended

			Six Months Ended 

			March 31, 2025

			March 31, 2024

			March 31, 2025

			March 31, 2024

			Expenses:

			Research and development

			$
			484,306

			$
			1,176,337

			$
			1,504,124

			$
			1,880,795

			General and administrative

			1,154,580

			1,044,137

			2,033,451

			2,197,108

			Loss from operations

			(1,638,886
			)

			(2,220,474
			)

			(3,537,575
			)

			(4,077,903
			)

			Other income:

			Reimbursement grant income

			52,268

			304,002

			353,463

			424,836

			Interest income

			265

			43,193

			1,931

			104,159

			Misc other income

			-

			14,766

			-

			14,766

			Foreign exchange (loss)

			(3,295
			)

			(2,018
			)

			(24,720
			)

			(4,840
			)

			49,238

			359,943

			330,674

			538,921

			Loss before income taxes

			(1,589,648
			)

			(1,860,531
			)

			(3,206,901